Annexon: Director buys 500,000 shares on three days - Insider purchases total $5.05 million!

The biotech company Annexon Inc. (ANNX) focuses on developing the next generation of complement inhibitors to stop neuroinflammation. The aim is to provide treatments for individuals suffering from severe neuroinflammatory diseases of the body, brain, and eye. These diseases involve inflammation of the nerves and surrounding tissues (in the body, brain, or eye). This inflammation is often not just a defensive reaction but targets the body’s own tissues (autoimmune reaction), leading to severe damage. A core program is Tanruprubart (ANX005),...